Neuropeptide Y (NPY) Y1 receptor-expressing neurons represent a critical subpopulation of neurons in the central nervous system that play pivotal roles in regulating energy homeostasis, stress responses, neuroprotection, and various neurological functions. The Y1 receptor (NPY1R) is one of the most widely expressed NPY receptors in the brain and belongs to the G protein-coupled receptor (GPCR) superfamily [@colmers1995]. These neurons are distributed throughout key brain regions including the hypothalamus, amygdala, hippocampus, and cortex, where they modulate numerous physiological and pathological processes relevant to neurodegenerative diseases [@stanley1993].
The NPY system has emerged as a major therapeutic target for neurodegenerative disorders, particularly Alzheimer's disease (AD) and Parkinson's disease (PD). Mounting evidence suggests that Y1 receptor signaling exerts neuroprotective effects through multiple mechanisms, including modulation of excitotoxicity, neuroinflammation, and oxidative stress [@pope2022]. Understanding the complex biology of NPY-Y1 receptor neurons is essential for developing novel therapeutic interventions for these devastating conditions.
Neuropeptide Y (NPY) Y1 receptor-expressing neurons represent a critical subpopulation of neurons in the central nervous system that play pivotal roles in regulating energy homeostasis, stress responses, neuroprotection, and various neurological functions. The Y1 receptor (NPY1R) is one of the most widely expressed NPY receptors in the brain and belongs to the G protein-coupled receptor (GPCR) superfamily [@colmers1995]. These neurons are distributed throughout key brain regions including the hypothalamus, amygdala, hippocampus, and cortex, where they modulate numerous physiological and pathological processes relevant to neurodegenerative diseases [@stanley1993].
The NPY system has emerged as a major therapeutic target for neurodegenerative disorders, particularly Alzheimer's disease (AD) and Parkinson's disease (PD). Mounting evidence suggests that Y1 receptor signaling exerts neuroprotective effects through multiple mechanisms, including modulation of excitotoxicity, neuroinflammation, and oxidative stress [@pope2022]. Understanding the complex biology of NPY-Y1 receptor neurons is essential for developing novel therapeutic interventions for these devastating conditions.
The NPY Y1 receptor (NPY1R) is a 36-kDa GPCR encoded by the NPY1R gene located on chromosome 4q31.3 in humans. The receptor consists of 384 amino acids with seven transmembrane domains characteristic of the rhodopsin family (Class A GPCRs) [@blomqvist1993]. NPY1R exhibits high affinity for NPY and related peptides including peptide YY (PYY) and pancreatic polypeptide (PP), with distinct structure-activity relationships governing ligand binding and receptor activation [@cabrele2000].
The receptor couples primarily to Gi/o proteins, leading to inhibition of adenylate cyclase, decreased cAMP production, and activation of G protein-gated inward-rectifying potassium (GIRK) channels [@kaga2011]. These signaling pathways mediate the characteristic hyperpolarizing effect of NPY on target neurons. Additionally, NPY1R activation can stimulate phospholipase C (PLC) signaling through Gq/11 proteins, generating inositol trisphosphate (IP3) and diacylglycerol (DAG) second messengers [@holzer2012].
The NPY1R gene is expressed in various brain regions with distinct developmental and activity-dependent regulation. Transcription factors including CREB (cAMP response element-binding protein) and AP-1 (activator protein-1) modulate NPY1R expression in response to neuronal activity and stress [@wahlestedt1993]. Studies have demonstrated that NPY1R mRNA levels are upregulated in the hippocampus following seizures and in cortical regions during neuroinflammation, suggesting activity-dependent regulation [@bitencourt2008].
Within the hypothalamus, NPY-Y1 receptor neurons are particularly abundant in the arcuate nucleus (ARC), where they co-express with agouti-related protein (AgRP) producing neurons [@chua1991]. The arcuate nucleus serves as a primary site for energy homeostasis regulation, with NPY-Y1 signaling critical for driving feeding behavior [@zarjevski1993]. Additionally, Y1 receptors are found in the paraventricular nucleus (PVN), where they modulate stress axis activation and corticosterone secretion [@heilig1994].
The amygdala contains high densities of NPY-Y1 receptor neurons, particularly in the central nucleus and basolateral complex. These neurons play crucial roles in emotional processing, anxiety, and fear conditioning [@rogan2007]. The hippocampus shows Y1 receptor expression throughout the CA1-CA3 regions and dentate gyrus, where they modulate synaptic plasticity, learning, and memory [@ghaddar2015]. Notably, hippocampal Y1 receptors are strategically positioned to influence cognitive processes affected in Alzheimer's disease.
In the cerebral cortex, Y1 receptor expression shows layer-specific patterns, with highest densities in layer II/III and layer V [@blomqv1993]. Cortical Y1 neurons participate in sensory processing, integration, and higher-order cognitive functions. Their distribution suggests roles in modulating cortical circuit excitability and information flow.
The nucleus tractus solitarius (NTS) in the brainstem contains Y1 receptor neurons that integrate visceral sensory information and regulate autonomic functions [@holzer2012]. These neurons are part of the neural circuitry controlling cardiovascular function, respiration, and gastrointestinal motility.
NPY-Y1 receptor neurons in the hypothalamus serve as key regulators of energy balance [@stanley1993]. When activated, they promote feeding behavior and reduce energy expenditure, counteracting the effects of leptin and insulin. The NPY-AgRP neuron population in the arcuate nucleus co-expresses Y1 receptors, creating an integrated system for metabolic regulation [@chua1991]. This system is dysregulated in obesity and metabolic syndrome, conditions that are themselves risk factors for neurodegenerative diseases.
The hypothalamic-pituitary-adrenal (HPA) axis is modulated by NPY-Y1 signaling, particularly in the paraventricular nucleus [@heilig1994]. Y1 receptor activation can either enhance or suppress stress responses depending on the brain region and context. Chronic stress leads to dysregulation of NPY-Y1 signaling, contributing to anxiety and depression-like behaviors [@sorensen2009].
Hippocampal NPY-Y1 receptors play important roles in synaptic plasticity and memory formation [@kaga2011]. Y1 receptor signaling modulates long-term potentiation (LTP) and long-term depression (LTD), the cellular correlates of learning. The receptor's location on glutamatergic synapses allows direct modulation of excitatory transmission [@ghaddar2015].
Amygdala Y1 receptors are essential for emotional processing and fear responses [@rogan2007]. NPY-Y1 signaling in this region modulates anxiety-like behaviors and emotional memory consolidation. Dysregulation of this system contributes to anxiety disorders and depression [@heilig1994].
NPY-Y1 receptor signaling has emerged as a potential therapeutic target for Alzheimer's disease [@tHowell2013]. Multiple mechanisms connect Y1 receptor function to AD pathogenesis:
Amyloid-Beta Modulation: Studies demonstrate that NPY protects against amyloid-beta (Aβ)-induced neurotoxicity through Y1 receptor activation [@pope2022]. NPY reduces Aβ-induced oxidative stress and caspase activation, promoting neuronal survival. The neuroprotective effects are blocked by Y1 receptor antagonists, confirming receptor specificity.
Neuroinflammation: NPY-Y1 signaling modulates neuroinflammatory responses in AD [@tHowell2013]. Y1 activation suppresses pro-inflammatory cytokine production from microglia, including IL-1β and TNF-α. This anti-inflammatory effect may slow disease progression by reducing chronic neuroinflammation that drives neurodegeneration.
synaptic Dysfunction: The hippocampus shows reduced NPY-Y1 receptor expression in AD models and patients [@yang2022]. This downregulation correlates with cognitive deficits and synaptic loss. Restoring Y1 signaling represents a therapeutic strategy to preserve synaptic function.
Glutamate Toxicity: NPY-Y1 receptors protect against excitotoxic cell death through Gi/o protein-mediated inhibition of voltage-gated calcium channels [@kaga2011]. This mechanism is particularly relevant to AD, where excitotoxicity contributes to neuronal loss.
NPY-Y1 receptor signaling shows promise for Parkinson's disease treatment [@shcherbina2020]:
Dopaminergic Neuroprotection: Y1 receptor activation protects dopaminergic neurons in the substantia nigra pars compacta (SNc) from degeneration [@shcherbina2020]. Studies in 6-hydroxydopamine (6-OHDA) and MPTP models demonstrate that NPY administration reduces dopaminergic neuron loss through Y1 receptor mechanisms.
Alpha-Synuclein Pathology: Emerging evidence suggests NPY-Y1 signaling may modulate alpha-synuclein aggregation and toxicity. The receptor's ability to reduce oxidative stress and neuroinflammation may slow the formation of Lewy bodies.
Motor Function: Beyond neuroprotection, Y1 agonists may improve motor function in PD models through modulation of basal ganglia circuits. The receptor's expression in the globus pallidus and subthalamic nucleus suggests roles in motor control.
NPY-Y1 receptor signaling has been investigated in ALS models. Motor neurons show Y1 receptor expression, and activation may modulate excitotoxic cell death. Studies demonstrate reduced disease progression in SOD1 G93A mice treated with NPY, though Y1 receptor involvement requires further characterization.
The NPY system is altered in Huntington's disease, with increased NPY expression in the striatum and cortex. Y1 receptors may protect medium spiny neurons from mutant huntingtin toxicity. However, the role of Y1 receptors in HD pathogenesis remains incompletely understood.
Several NPY-Y1 receptor agonists are in development for neurodegenerative diseases. These compounds aim to replicate the neuroprotective effects of endogenous NPY while providing better pharmacokinetic properties. Selective Y1 agonists avoid Y2 and Y5 receptor activation, potentially reducing side effects associated with pan-NPY receptor activation.
Clinical Trials: While no Y1-selective agonists have reached late-stage clinical trials for neurodegenerative indications, several candidates are in preclinical development. Pharmacokinetic challenges including blood-brain barrier penetration and receptor desensitization remain key hurdles.
Paradoxically, Y1 receptor antagonists have also been investigated for neurological applications. In acute settings, Y1 blockade may reduce deleterious effects of excessive NPY release. However, chronic Y1 blockade generally shows unfavorable effects on mood and energy balance.
Viral vector-mediated NPY delivery represents an alternative approach to enhance Y1 signaling. Adeno-associated virus (AAV) vectors can deliver NPY genes to specific brain regions, providing long-term expression. This approach has shown promise in preclinical PD models.
NPY-Y1 agonists may synergize with other neuroprotective strategies. Combination with tau-targeting therapies, amyloid-lowering agents, or dopaminergic treatments could provide additive benefits. Understanding the optimal sequencing and dosing of combination approaches remains an active area of research.
NPY1R couples primarily to Gi/o proteins, leading to multiple downstream effects [@kaga2011]:
In some neuron types, NPY1R couples to Gq proteins, activating:
NPY1R can signal through beta-arrestin pathways independent of G protein coupling. This mechanism may contribute to receptor desensitization and alternative signaling effects.
NPY and NPY1R expression may serve as biomarkers for neurodegenerative disease progression. Cerebrospinal fluid (CSF) NPY levels are elevated in AD and PD patients, reflecting neuronal stress or compensatory responses. Peripheral blood monocyte NPY1R expression may reflect central nervous system changes.
Developing Y1-targeted therapeutics faces several challenges:
Identifying patients most likely to respond to Y1-targeted therapies may improve clinical trial success. Genetic variants in NPY1R may influence treatment response. Additionally, disease stage and pathological subtype may influence Y1 agonist efficacy.
Recent studies have employed single-cell RNA sequencing to characterize NPY-Y1 neuron populations. These studies reveal unexpected heterogeneity within Y1-expressing neurons, with distinct subpopulations in different brain regions. Understanding this heterogeneity will enable more targeted therapeutic approaches.
Optogenetic and chemogenetic tools allow circuit-specific manipulation of NPY-Y1 neurons. These approaches are revealing the precise circuits through which Y1 signaling influences behavior and disease. Future therapies may target specific circuits while avoiding systemic side effects.
Advanced delivery systems including nanoparticles and implantable devices may enable better Y1 agonist delivery to the brain. These technologies could overcome current pharmacokinetic limitations and enable chronic dosing.
This page links to related wiki content including: